



**FULBRIGHT & JAWORSKI L.L.P.**  
A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
[WWW.FULBRIGHT.COM](http://WWW.FULBRIGHT.COM)

**MBWILSON@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3035**

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

TECH CENTER 1600/2900

June 20, 2003

**CERTIFICATE OF MAILING**  
**37 C.F.R. 1.8**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RE: SN 09/974,753 "METHODS AND COMPOSITIONS FOR INDUCING  
AUTOIMMUNITY IN THE TREATMENT OF CANCERS" - Alan J. Schroit  
Client Ref.: MDA97-044DIV1 Our Ref. UTSC:594USD1

**Commissioner:**

Please find enclosed:


1. Amendment; and Response to the Office Action Dated March 20, 2003 (with attached Exhibits A-C);
2. Form PTO-1449 previously filed with PTO, along with the following references which are missing from PTO's file:
  - a. Creaven *et al.*, "Initial Clinical Trial of Muramyl Tripeptide Derivative (MTP-PE) Encapsulated in Liposomes: an Interim Report," *UCLA Symp. Mol. Cell. Biol.*, New Ser 89: 297-303, 1989, Abstract Only;
  - b. Gupta *et al.*, "Adjuvants for human vaccines—current status, problems and future prospects," *Vaccine*, 13(14):1263-1276, 1995; and
  - c. Henry-Michelland *et al.*, "Attachment of antibiotics to nanoparticles: preparation, drug-release and antimicrobial activity in vitro," *Int. J. Pharm.*, 35:121-127, 1987.

25308309.1

Commissioner for Patents  
June 20, 2003  
Page 2

3. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UTSC:594USD1.

Very truly yours,  


Mark B. Wilson  
Reg. No. 37,259

MBW/djm  
Encl.